134 related articles for article (PubMed ID: 37171692)
41. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Fukuda M; Nakamura Y; Kasai T; Nagashima S; Nakatomi K; Doi S; Nakano H; Takatani H; Fukuda M; Kinoshita A; Soda H; Tsukamoto K; Oka M; Kohno S;
J Thorac Oncol; 2009 Jun; 4(6):741-5. PubMed ID: 19404211
[TBL] [Abstract][Full Text] [Related]
42. Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.
Jalal SI; Hanna N; Zon R; Masters GA; Borghaei H; Koneru K; Badve S; Prasad N; Somaiah N; Wu J; Yu Z; Einhorn L
Am J Clin Oncol; 2017 Aug; 40(4):329-335. PubMed ID: 25503432
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of amrubicin as a third or later line of chemotherapy for advanced non-small cell lung cancer.
Igawa S; Sasaki J; Ishihara M; Otani S; Maki S; Hiyoshi Y; Kasajima M; Katono K; Takakura A; Masuda N
Chemotherapy; 2013; 59(2):99-105. PubMed ID: 24021914
[TBL] [Abstract][Full Text] [Related]
44. Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
Spigel DR; Hainsworth JD; Shipley DL; Mekhail TM; Zubkus JD; Waterhouse DM; Daniel DB; Burris HA; Greco FA
Lung Cancer; 2018 Mar; 117():38-43. PubMed ID: 29496254
[TBL] [Abstract][Full Text] [Related]
45. Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer.
Igawa S; Ryuge S; Fukui T; Otani S; Kimura Y; Katono K; Takakura A; Kubota M; Mitsufuji H; Katagiri M; Yanase N; Masuda N
Int J Clin Oncol; 2010 Oct; 15(5):447-52. PubMed ID: 20464623
[TBL] [Abstract][Full Text] [Related]
46. [A case of relapsed small-cell lung cancer successfully treated by administration of amrubicin].
Mori H; Tanaka H
Nihon Kokyuki Gakkai Zasshi; 2007 Dec; 45(12):967-70. PubMed ID: 18186244
[TBL] [Abstract][Full Text] [Related]
47. Prognosis of small-cell lung cancer since the introduction of amrubicin.
Suzuki H; Hirashima T; Kobayashi M; Sasada S; Okamoto N; Tamiya M; Matsuura Y; Morishita N; Uehara N; Matsui K; Kawase I
Med Oncol; 2011 Dec; 28(4):1430-5. PubMed ID: 20632217
[TBL] [Abstract][Full Text] [Related]
48. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.
Yoshioka H; Katakami N; Okamoto H; Iwamoto Y; Seto T; Takahashi T; Sunaga N; Kudoh S; Chikamori K; Harada M; Tanaka H; Saito H; Saka H; Takeda K; Nogami N; Masuda N; Harada T; Kitagawa H; Horio H; Yamanaka T; Fukuoka M; Yamamoto N; Nakagawa K
Ann Oncol; 2017 Feb; 28(2):285-291. PubMed ID: 28426104
[TBL] [Abstract][Full Text] [Related]
49. Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
Kaneda H; Okamoto I; Hayashi H; Yoshioka H; Miyazaki M; Kudoh S; Kimura T; Sugiura T; Sawa T; Takeda K; Iwamoto Y; Satouchi M; Akita K; Saito H; Goto I; Shibata K; Fukuoka M; Nakagawa K;
J Thorac Oncol; 2010 Jan; 5(1):105-9. PubMed ID: 19884859
[TBL] [Abstract][Full Text] [Related]
50. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
[TBL] [Abstract][Full Text] [Related]
51. Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer.
Watanabe H; Ikesue H; Oshiro M; Nagata K; Mishima K; Takada A; Suetsugu K; Sueyasu M; Egashira N; Harada T; Takayama K; Nakanishi Y; Oishi R
Chemotherapy; 2012; 58(6):419-25. PubMed ID: 23295219
[TBL] [Abstract][Full Text] [Related]
52. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as
Second-line Treatment for Small Cell Lung Cancer].
Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
[TBL] [Abstract][Full Text] [Related]
53. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
[TBL] [Abstract][Full Text] [Related]
54. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
[TBL] [Abstract][Full Text] [Related]
55. A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.
Sekine I; Okamoto H; Horai T; Nakagawa K; Ohmatsu H; Yokoyama A; Katakami N; Shibuya M; Saijo N; Fukuoka M
Clin Lung Cancer; 2014 Mar; 15(2):96-102. PubMed ID: 24361248
[TBL] [Abstract][Full Text] [Related]
56. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Ikeda T; Fukuda M; Nakamura Y; Kinoshita A; Senju H; Nakano H; Kitazaki T; Ogawara D; Taniguchi H; Motoshima K; Yamaguchi H; Nakatomi K; Shimada M; Nagashima S; Tsukamoto K; Kohno S;
Cancer Chemother Pharmacol; 2014 Sep; 74(3):497-502. PubMed ID: 25034978
[TBL] [Abstract][Full Text] [Related]
57. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract.
Araki T; Takashima A; Hamaguchi T; Honma Y; Iwasa S; Okita N; Kato K; Yamada Y; Hashimoto H; Taniguchi H; Kushima R; Nakao K; Boku N; Shimada Y
Anticancer Drugs; 2016 Sep; 27(8):794-9. PubMed ID: 27341105
[TBL] [Abstract][Full Text] [Related]
58. [Prognostic factors and response of chemotherapy including amrubicin in small cell lung cancer patients].
Wang Y; Liu L; Wu M; Zhong J; Liu X; An T; Zhao J; Duan J; Wang Z; Zhou M; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2015 Apr; 38(4):261-6. PubMed ID: 26268231
[TBL] [Abstract][Full Text] [Related]
59. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients.
Kushiro K; Watanabe S; Goto Y; Fujisaki T; Yanagimura N; Ohtsubo A; Shoji S; Nozaki K; Tanaka T; Saida Y; Sato Y; Ota T; Koshio J; Hayashi Y; Miyabayashi T; Matsumoto N; Ichikawa K; Koyama K; Kikuchi T
Transl Lung Cancer Res; 2022 Sep; 11(9):1858-1865. PubMed ID: 36248339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
